Preoperative SGLT2 inhibitor therapy was associated with significantly reduced 1-year all-cause mortality following surgical aortic valve replacement.
Does preoperative SGLT2i therapy reduce 1-year all-cause mortality in patients undergoing surgical aortic valve replacement?
Patients undergoing surgical aortic valve replacement (as discussed from the index study by Yan et al.)
Preoperative sodium-glucose transport protein 2 inhibitor (SGLT2i) therapy
1-year all-cause mortalityhard clinical
This letter emphasizes that studies evaluating SGLT2 inhibitors in surgical aortic valve replacement should account for diastolic dysfunction, metabolic syndrome, and baseline risk scores to accurately interpret mortality and morbidity outcomes.
Building similarity graph...
Analyzing shared references across papers
Loading...
Rohan Magoon
Jes Jose
The Cardiothoracic Surgeon
Building similarity graph...
Analyzing shared references across papers
Loading...
Magoon et al. (Sat,) conducted a letter in Surgical aortic valve replacement. Sodium-glucose transport protein 2 inhibitor (SGLT2i) was evaluated on 1-year all-cause mortality. Preoperative SGLT2 inhibitor therapy was associated with significantly reduced 1-year all-cause mortality following surgical aortic valve replacement.
synapsesocial.com/papers/6a025efac9581ed855361b20 — DOI: https://doi.org/10.1186/s43057-026-00202-7